List of Excipients in Branded Drug RHOPHYLAC

Rhophylac Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Rhophylac is a plasma-derived anti-D immunoglobulin used to prevent Rh(D) alloimmunization in Rh-negative patients. Its commercial position depends less on excipient patent protection than on antibody potency, viral safety, plasma supply, regulatory manufacturing controls, and reliable obstetric distribution. The formulation uses a conservative, low-complexity excipient system designed to preserve immunoglobulin stability while minimizing clinical and regulatory risk.

What excipients are used in Rhophylac?

Rhophylac is supplied as a ready-to-use injectable solution containing human anti-D immunoglobulin. Public product information identifies human albumin, glycine, sodium chloride, and water for injection as formulation components. The U.S. prescribing information also identifies polysorbate 80 in the formulation information for the marketed product.[1,2]

Formulation element	Strategic function
Human albumin	Protein stabilizer and protection against surface adsorption
Glycine	Buffering and protein-stabilization support
Sodium chloride	Tonicity adjustment
Polysorbate 80	Surfactant control of interfacial stress and aggregation
Water for injection	Sterile liquid vehicle

The formulation is preservative-free and supplied in a single-use presentation. The product is intended for intravenous or intramuscular administration, depending on the indication and clinical circumstances.[1]

Why does Rhophylac use a simple excipient system?

Immunoglobulin products are vulnerable to aggregation, fragmentation, adsorption to container surfaces, and loss of biological activity. A formulation based on albumin, glycine, sodium chloride, and surfactant addresses these risks without introducing complex excipient combinations.

The formulation also supports a ready-to-use product. Hospitals do not need to reconstitute a lyophilized vial, which reduces preparation steps and limits compounding error. For obstetric use, where administration often occurs around delivery, a prefilled liquid presentation has operational value.

What formulation patents protect Rhophylac?

Publicly available product information does not establish a distinct, currently enforceable Rhophylac excipient patent estate. Rhophylac is a plasma-derived biologic, and its commercial protection is primarily linked to manufacturing know-how, donor-plasma controls, fractionation, purification, viral clearance, potency testing, and regulatory approvals.

Rhophylac is not a conventional small-molecule product listed in the FDA Orange Book with an ANDA-based patent certification framework. Biologic competition is evaluated through the Biologics Price Competition and Innovation Act pathway, including 351(k) biosimilar applications, rather than a standard abbreviated new drug application.[3,4]

Are Rhophylac excipients likely to create blocking IP?

Excipient composition alone is unlikely to create a durable barrier. Human albumin, glycine, sodium chloride, polysorbate 80, and water for injection are established pharmaceutical excipients. A potentially stronger formulation claim would need to distinguish the product through a specific combination of concentration ranges, pH, protein concentration, stability profile, aggregation control, container system, or manufacturing process.

For a follow-on product, the more meaningful freedom-to-operate questions concern:

• Anti-D antibody source and donor-plasma procurement
• Fractionation and purification process
• Viral inactivation and removal
• Immunoglobulin potency and specificity
• Low-temperature storage and shipping
• Container closure and silicone or elastomer compatibility
• Manufacturing site qualification
• Clinical comparability and immunogenicity controls

A competitor could generally avoid direct formulation infringement by using a different stabilizer system, such as sorbitol, proline, trehalose, or another surfactant, subject to product quality and regulatory requirements. That strategy would create development risk because changing excipients in a plasma-derived immunoglobulin can affect aggregation, potency, tolerability, and shelf life.

When does Rhophylac lose exclusivity?

Rhophylac’s U.S. biologic exclusivity period has expired. FDA approved Rhophylac in 2004, and the 12-year reference-product exclusivity period applicable to biologics approved under the modern BPCIA framework would not remain a current barrier to biosimilar filing.[3,5]

Exclusivity or protection category	Rhophylac position
FDA approval	Approved in 2004
12-year reference biologic exclusivity	Expired
Small-molecule Hatch-Waxman exclusivity	Not applicable
Orange Book patent listing	Not the primary framework
Biosimilar pathway	Potentially available under section 351(k)
Orphan exclusivity	Not identified as the principal product protection
Manufacturing protection	Material commercial barrier

Expiration of regulatory exclusivity does not create automatic market entry. A follow-on anti-D product must demonstrate comparable quality, safety, purity, potency, and clinical performance. Plasma-derived products face manufacturing and supply barriers that can be more significant than nominal patent expiry.

What is the FDA regulatory status of Rhophylac?

Rhophylac is an FDA-approved biologic licensed through a biologics license application. It is indicated for prevention of Rh(D) immunization in non-sensitized Rh-negative patients, including use during pregnancy, after delivery, and following certain obstetric events.[1]

The product’s regulatory value comes from an established safety record, validated manufacturing, and a label covering multiple clinical situations. Those attributes make substitution more difficult than substitution between many small-molecule injectables.

FDA-approved anti-D immunoglobulin products include Rhophylac, RhoGAM, MICRhoGAM, HyperRHO, and WinRho SDF, although products differ in indications, presentations, dosage strengths, administration routes, and manufacturing platforms.[1,6,7]

How does Rhophylac compare with competing anti-D products?

Product	Sponsor or manufacturer	Product type	Key commercial distinction
Rhophylac	CSL Behring	Human anti-D immunoglobulin	Ready-to-use 300 mcg presentation; IV or IM use
RhoGAM	Kedrion/related commercial organizations depending on market	Human anti-D immunoglobulin	Established U.S. obstetric brand
MICRhoGAM	Kedrion	Lower-dose anti-D immunoglobulin	Used for selected early-pregnancy or small fetomaternal hemorrhage settings
HyperRHO	Grifols	Human anti-D immunoglobulin	Alternative branded supply
WinRho SDF	Saol Therapeutics and manufacturing partners	Anti-D immunoglobulin	Broader hematology positioning, including immune thrombocytopenic purpura in relevant markets

Product-level competition centers on supply continuity, dose availability, hospital contracts, route of administration, physician familiarity, and reimbursement. Excipient differentiation has secondary importance unless it produces a measurable benefit in stability, tolerability, storage, or administration.

What commercial opportunities exist for Rhophylac excipients?

The strongest opportunities are formulation-adjacent rather than excipient-licensing opportunities.

1. Low-volume and prefilled delivery

A prefilled syringe can reduce preparation time and dosing errors. A next-generation product could optimize syringe geometry, needle configuration, dead volume, and administration ergonomics. Those improvements could support hospital purchasing and outpatient obstetric use.

The opportunity is strongest where the product can preserve the current liquid formulation while improving usability. A novel device or container system may create more defensible IP than a minor excipient substitution.

2. Improved thermal stability

Anti-D immunoglobulin products require controlled storage. A formulation that tolerates short excursions above the labeled temperature range could reduce wastage during transport and hospital inventory management.

Potential approaches include:

• Adjusted glycine or amino-acid stabilization
• Alternative surfactant systems
• Improved albumin concentration
• Reduced particulate formation
• Low-binding container materials
• Optimized pH and ionic strength

These changes would require comparative stability, potency, aggregation, subvisible-particle, and extractables and leachables studies.

3. Longer shelf life

An extended shelf life could improve inventory economics, particularly for hospitals that maintain emergency obstetric stock. Shelf-life gains must be demonstrated without compromising anti-D potency or increasing immunoglobulin aggregates.

A successful formulation could support licensing to regional plasma-product manufacturers, especially where imported cold-chain products have high logistics costs.

4. Alternative administration routes

Subcutaneous anti-D immunoglobulin could reduce dependence on intramuscular administration and improve patient acceptability. This is a development opportunity, not an established Rhophylac label attribute. Subcutaneous delivery would require evaluation of injection volume, local tolerability, absorption, pharmacokinetics, and protection against Rh(D) alloimmunization.

The excipient system may need to change for subcutaneous use. Higher viscosity, local concentration, surfactant exposure, and injection-site tolerability could become limiting factors.

5. Dose flexibility

A portfolio with 50 mcg, 100 mcg, and 300 mcg presentations could target different clinical scenarios and reduce product waste. Smaller presentations may be commercially relevant in early pregnancy, miscarriage, abortion care, invasive procedures, and lower-volume fetomaternal hemorrhage.

The main barriers are manufacturing economics and demand fragmentation. Lower-dose products may improve clinical fit but increase packaging and inventory complexity.

What manufacturing and IP barriers affect generic or biosimilar entry?

A conventional generic launch is unlikely because Rhophylac is a biologic. A biosimilar or follow-on product would need to address the full product lifecycle, including:

1. Donor eligibility and plasma collection
2. Anti-D antibody titer and specificity
3. Fractionation yield
4. Purification consistency
5. Viral inactivation and clearance
6. Host-cell and process impurity control
7. Potency assay comparability
8. Aggregation and particle control
9. Container closure integrity
10. Clinical immunogenicity and safety

Plasma availability is a structural barrier. Manufacturers need sufficient anti-D-positive donor plasma with consistent antibody characteristics. Capacity cannot be added quickly, and supply disruption can affect the entire market.

Manufacturing know-how is also difficult to replicate from public disclosures. A competitor may design around formulation claims but still face a long process-development timeline and substantial validation costs.

Which companies are positioned to challenge Rhophylac?

Potential competitive pressure comes from established plasma-derived immunoglobulin manufacturers rather than conventional generic companies. Relevant competitors include Kedrion, Grifols, and manufacturers associated with HyperRHO and WinRho SDF. The competitive threat depends on product availability, FDA or foreign approval, hospital contracting, and anti-D plasma access.

A biosimilar entrant would have the greatest commercial impact if it can offer:

• Equivalent 300 mcg dosing
• Reliable obstetric supply
• Competitive hospital pricing
• A ready-to-use syringe
• Broad route-of-administration compatibility
• Comparable shelf life
• Strong pharmacovigilance and manufacturing documentation

What patent litigation and settlement risks affect Rhophylac?

No major public Orange Book-style patent litigation framework is associated with Rhophylac. The principal legal risks are more likely to involve biologic manufacturing patents, process claims, trade secrets, regulatory exclusivity, supply agreements, and device patents.

A biosimilar applicant could face patent disputes under the BPCIA patent dance if the reference sponsor asserts manufacturing, formulation, or use claims. Method-of-use claims could be relevant to pregnancy prophylaxis, postpartum administration, or treatment after fetomaternal hemorrhage, although their enforceability would depend on claim scope and expiration.

Settlement agreements could delay market entry if a biosimilar sponsor and reference-product holder resolve patent claims. No publicly established Rhophylac-specific settlement should be assumed without a case-level review of court filings and regulatory records.

How strong is the Rhophylac patent estate?

The commercial estate is stronger in manufacturing and regulatory execution than in excipient exclusivity. A practical assessment is:

Protection category	Relative strength
Excipient composition	Low to moderate
Ready-to-use liquid presentation	Moderate if covered by enforceable device or formulation claims
Anti-D potency and product quality	High operational barrier, limited exclusivity by itself
Plasma sourcing	High commercial barrier
Fractionation and purification	High know-how barrier
Viral safety process	High regulatory barrier
Obstetric brand recognition	Moderate commercial protection
Biosimilar regulatory pathway	Open in principle, demanding in execution

What revenue exposure does Rhophylac face?

Revenue exposure is concentrated in obstetric prophylaxis. Demand is tied to the number of Rh-negative pregnancies, prenatal screening, delivery volume, clinical guidelines, and availability of alternatives.

Long-term demand may face pressure from fetal RhD genotyping, improved patient selection, changes in clinical practice, and potential development of recombinant or synthetic anti-D products. Those technologies could reduce dependence on donor plasma but remain technically and clinically demanding.

The near-term commercial opportunity remains operational: dependable supply, lower administration burden, dose optimization, and lower wastage. A differentiated excipient strategy is valuable when it supports those outcomes and does not increase manufacturing complexity.

Key Takeaways

• Rhophylac uses a conventional stabilizing system centered on human albumin, glycine, sodium chloride, polysorbate 80, and water for injection.
• Its major competitive barriers are plasma supply, manufacturing validation, potency control, viral safety, and regulatory compliance.
• FDA biologic exclusivity has expired, but biosimilar entry remains difficult.
• Rhophylac is not primarily protected through an Orange Book patent framework.
• The best formulation opportunities are longer shelf life, improved thermal stability, prefilled delivery, low-volume dosing, and possible subcutaneous administration.
• Excipient changes alone are unlikely to support durable commercial differentiation unless they produce measurable stability, usability, or supply-chain benefits.
• A follow-on entrant would compete against established plasma-product companies, not only traditional generic manufacturers.

FAQs

Can Rhophylac be reformulated with trehalose instead of glycine?

Yes, a follow-on product could investigate trehalose or another stabilizer, but it would require extensive comparability and stability work. The alternative excipient would need to preserve anti-D potency and control aggregation, particles, and local tolerability.

Does Rhophylac contain preservatives?

The marketed product is described as preservative-free. Its single-use presentation reduces the need for antimicrobial preservatives.[1,2]

Could a biosimilar Rhophylac use different excipients?

Yes. A biosimilar does not necessarily need an identical excipient system, but differences must be justified through analytical, clinical, and regulatory data. The formulation cannot create clinically meaningful differences in safety, tolerability, or performance.

Is recombinant anti-D a commercial substitute for Rhophylac?

Recombinant anti-D could eventually reduce reliance on human plasma, but it would require demonstrated antibody specificity, potency, safety, scalable production, and regulatory approval. It remains a technology-development opportunity rather than a routine substitute.

Which Rhophylac improvement is most commercially attractive?

A ready-to-use, low-volume presentation with improved thermal stability and a longer shelf life is likely to offer the clearest commercial value. It addresses hospital workflow, wastage, and supply-chain costs without requiring a fundamental change in the antibody product.

References

1. U.S. Food and Drug Administration. (2024). Rhophylac: Prescribing information. CSL Behring LLC.

2. European Medicines Agency. (2024). Rhophylac: Summary of product characteristics. European Union.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar biological products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

5. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-821 (2010).

6. U.S. Food and Drug Administration. (2024). RhoGAM Ultra-Filtered PLUS: Prescribing information. Kedrion Biopharma Inc.

7. U.S. Food and Drug Administration. (2024). WinRho SDF: Prescribing information. Saol Therapeutics Inc.